News
Press Release
4Moving Biotech Secures €7.6M France 2030 Grant for Pioneering First-In-Class Disease-Modifying Osteoarthritis Drug
Clinical Trial Press Release
Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis
Gouvernance News
Luc Boblet joins 4Moving Biotech as its Chief Executive Officer
Financial News Press Release
4Moving Biotech dans la dernière édition de Biotec Finances
Clinical Trial Gouvernance News Press Release
4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients
Gouvernance News
4Moving Biotech forms its Scientific Advisory Board
End of content